Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEPEN vs BAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Wilson's disease,Cystinuria,Rheumatoid arthritis,Heavy metal poisoning (e.g., lead, mercury)
Arsenic poisoning,Mercury poisoning,Lead poisoning (adjunct to edetate calcium disodium),Acute gold poisoning,Wilson's disease (investigational)
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Penicillamine is metabolized via oxidation to disulfides. It is primarily excreted in urine as unchanged drug and metabolites.
Primarily hepatic; undergoes oxidation and conjugation; metabolites excreted renally.
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
80%; primarily to albumin.
BAL is extensively bound to plasma proteins, primarily albumin, with protein binding >90%.
0.1-0.4 L/kg; indicates limited extravascular distribution, mainly confined to plasma and interstitial fluid.
Volume of distribution is approximately 3.5 L/kg, indicating extensive distribution into tissues, including brain and intracellular spaces.
Oral: 40-70% (variable due to food and formulation).
BAL is not administered orally due to poor absorption and gastrointestinal irritation. Given intravenously, bioavailability is 100%. Intramuscular bioavailability is similar but with slower absorption.
GFR 30-59 m L/min: 250 mg every 8-12 hours; GFR 15-29 m L/min: 250 mg every 12-24 hours; GFR <15 m L/min: 250 mg every 24 hours or avoid use.
GFR 10-50 m L/min: reduce frequency to every 6-8 hours; GFR <10 m L/min: reduce frequency to every 8-12 hours.
No adjustment recommended for mild to moderate impairment (Child-Pugh A or B); avoid use in severe impairment (Child-Pugh C) due to increased risk of hepatotoxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% and monitor for hepatotoxicity.
Children >1 year: 10-15 mg/kg/day divided every 6-8 hours, maximum 500 mg/day.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days; maximum 100 mg per dose.
Start at lower end of dosing range (250 mg twice daily) due to age-related renal function decline; monitor renal function and adjust based on creatinine clearance.
Start at 3 mg/kg IM every 6 hours; adjust based on renal function, monitor for hypotension and pain at injection site.
None.
None.
Bone marrow suppression (leukopenia, thrombocytopenia, aplastic anemia),Proteinuria and nephrotic syndrome,Autoimmune reactions (lupus-like syndrome, myasthenia gravis),Hepatotoxicity,Severe skin reactions (e.g., pemphigus, Stevens-Johnson syndrome),Monitor renal function, blood counts, and urinalysis regularly
Monitor renal function and serum electrolytes during therapy.,Can cause hypertension, tachycardia, and myocardial ischemia; use cautiously in cardiovascular disease.,May induce hemolytic anemia in patients with G6PD deficiency.,Injection site reactions and sterile abscesses may occur.,Iron deficiency is a known adverse effect due to iron chelation.
History of penicillamine-induced aplastic anemia or agranulocytosis,Pregnancy (relative contraindication due to teratogenicity),Renal insufficiency (avoid in severe impairment),Hypersensitivity to penicillamine
Hypersensitivity to BAL or any component.,Hepatic insufficiency (unless benefit outweighs risk).,Iron poisoning (forms toxic complex).,Concurrent use with cadmium or selenium (increased toxicity).
Avoid foods high in copper (e.g., liver, shellfish, nuts, chocolate, mushrooms) during treatment for Wilson disease. For cystinuria, maintain high fluid intake (at least 3-4 liters/day) and reduce sodium and animal protein to decrease cystine excretion. Vitamin B6 supplementation may be needed as DEPEN can increase pyridoxine requirements.
Avoid alcohol and caffeine. Maintain adequate hydration. No specific food restrictions, but ensure iron-rich foods are avoided if concurrent iron poisoning suspected (though BAL not indicated for iron).
Penicillamine (Depen) is associated with severe fetal malformations including cutis laxa and skeletal abnormalities when used during pregnancy. First trimester exposure carries highest risk; use is contraindicated unless necessary for maternal conditions like Wilson's disease or cystinuria. Second and third trimester use may cause fetal connective tissue disorders.
Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.
Penicillamine is excreted into breast milk in low amounts; M/P ratio not well defined. Potential for infant toxicity (e.g., rash, bone marrow suppression). Caution advised; monitor infant for adverse effects. Alternative therapies preferred.
BAL (dimercaprol) is excreted into breast milk; M/P ratio unknown. Limited data; exercise caution and consider temporary cessation of breastfeeding during therapy.
No standard dose adjustment defined; use lowest effective dose. Pharmacokinetics not well studied; increased clearance may require dose titration. Monitor clinical response and copper levels in Wilson's disease.
No specific dose adjustments recommended in pregnancy; monitor for increased volume of distribution and potential need for higher doses if toxicity persists.
DEPEN (penicillamine) is a chelating agent used for Wilson disease, cystinuria, and rheumatoid arthritis. Monitor for proteinuria and hematuria due to immune complex nephropathy. Cross-sensitivity with penicillin possible. Administer on empty stomach for Wilson disease; with meals for cystinuria to reduce GI upset. Avoid concomitant use with other nephrotoxic drugs.
BAL (dimercaprol) is used as a chelating agent for heavy metal poisoning, particularly arsenic, lead, and mercury. Administer deep IM only; avoid IV due to risk of hemolysis. Monitor blood pressure closely as hypertension can occur. Contraindicated in peanut allergy due to peanut oil vehicle. Administer with alkaline urine to protect kidneys.
Take DEPEN on an empty stomach at least 1 hour before or 2 hours after meals, unless otherwise directed for cystinuria.,Do not skip doses; consistent intake is critical for Wilson disease to prevent copper accumulation.,Report any signs of infection, unusual bleeding, skin rash, or changes in urine color or output immediately.,Avoid alcohol completely as it may increase risk of liver toxicity.,Use effective contraception during therapy as DEPEN can cause fetal harm.,Have regular blood and urine tests as ordered to monitor for side effects.
This medication is given as an injection into a muscle.,You may experience a metallic taste, headache, or nausea.,Report any signs of allergic reaction such as rash or difficulty breathing.,Avoid alcohol while on this medication.,Do not drive or operate heavy machinery until you know how this drug affects you.
No interactions on record
"Pregabalin, a gabapentinoid, enhances the inhibitory effects of GABA by binding to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Dapiprazole, an α1-adrenoceptor antagonist used for miosis, can have its therapeutic efficacy increased when combined with pregabalin due to additive central nervous system depression. This interaction may result in enhanced sedation, dizziness, and psychomotor impairment, potentially increasing the risk of falls and cognitive dysfunction."
"Pregabalin and pravastatin may exhibit an additive risk of musculoskeletal adverse effects, particularly myopathy and rhabdomyolysis, due to their overlapping effects on muscle cells. Pregabalin can cause dose-related muscle damage, while pravastatin inhibits HMG-CoA reductase, leading to reduced skeletal muscle integrity. This combination may potentiate serum creatine kinase elevations and increase the likelihood of clinical myopathy, especially in patients with predisposing factors such as renal impairment or concomitant use of other myotoxic agents."
"Pregabalin may cause fluid retention and peripheral edema, which can precipitate or exacerbate heart failure, especially in patients with pre-existing cardiac risk factors. Rosiglitazone, a thiazolidinedione, also promotes fluid retention and increases plasma volume via PPAR-γ-mediated renal effects. When combined, the additive fluid-retaining properties of both drugs can synergistically elevate the risk of new-onset or worsening heart failure, particularly in patients with reduced left ventricular function or NYHA Class III/IV status."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEPEN vs BAL, answered by our medical review team.
DEPEN is a Chelating Agent that works by Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.. BAL is a Chelating Agent that works by Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEPEN and BAL depend on the specific clinical indication. These are both Chelating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEPEN is: 250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.. The standard adult dose of BAL is: 3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEPEN and BAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEPEN is classified as Category C. Penicillamine (Depen) is associated with severe fetal malformations including cutis laxa and skeletal abnormalities when used during pregnancy. First trimester exposure carries hig. BAL is classified as Category C. Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.